|
|
Article: Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2007.
- Article from:
- PR Newswire
- Article date:
- May 16, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
-- Data from Phase III pivotal trial demonstrate safety and efficacy of first FDA-approved nebulized formoterol fumarate for patients with moderate to severe COPD --
NAPA, Calif., May 16 /PRNewswire/ -- Dey, L.P. announced that two clinical data presentations will be given at the International Conference of the American Thoracic Society (ATS) on Sunday, May 20, at the Moscone Center in San Francisco. The presentations will detail Phase III clinical data demonstrating the safety and efficacy of Perforomist(TM) (formoterol fumarate) Inhalation Solution, approved on May 11 by the FDA for long-term, twice-daily maintenance treatment of bronchoconstriction for ...